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Introduction
The links between smoking and increased morbid-
ity and mortality have been long established, and
current trends indicate that of the one billion
smokers worldwide, 500 million will die prema-
turely from smoking-related diseases (1). Smoking
has been shown to have harmful effects on numer-
ous organs of the body and the list of diseases
where smoking has been recognised as a contribu-
tory factor is extensive (2). It has long been
accepted that cigarette smoking is a classical and
major risk factor in the development of cardiovas-
cular disease (CVD) and atherosclerosis (3,4). More
recently, it has been recognised that CVD contains
a component of inﬂammation and has even been
referred to as an inﬂammatory disease (5,6). In
addition, a link has been established between sev-
eral other chronic inﬂammatory diseases and smok-
ing, including chronic obstructive pulmonary
disease (COPD) (7), rheumatoid arthritis, systemic
lupus erythematosus (8) and Crohn’s disease (9).
Although the mechanisms linking smoking to these
diseases are not well understood, interest in the
relationship between inﬂammatory markers and
smoking has been gathering pace in an attempt to
provide explanations for smoking-mediated morbid-
ity and mortality.
One such inﬂammatory marker, C-reactive protein
(CRP), may be easily and sensitively measured in a
variety of clinical situations to monitor disease pro-
gression (10). This review will discuss the relation-
ship between smoking behaviour and levels of CRP,
focusing on the use of CRP measurement to predict
long-term health in smokers and the outcome of
smoking cessation on CRP levels.
CRP as a marker for acute and chronic
inﬂammation
C-reactive protein is an acute phase plasma protein,
synthesised in response to general inﬂammatory epi-
sodes within the body (11,12). It is produced prin-
cipally by hepatocytes as indicated in Figure 1, but
can also be expressed by adipocytes (13) and cul-
tured coronary artery smooth muscle cells (14),
suggesting that localised inﬂammation can induce
CRP expression. Indeed, CRP has been detected by
immunoﬂuorescence in atherosclerotic plaques from
human coronary arteries (15). The acute inﬂamma-
tory response is induced by numerous challenges to
the body, including infections and trauma, and
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SUMMARY
Background: Cigarette smoking is a classical and a major risk factor in the devel-
opment of several diseases with an inﬂammatory component, including cardiovas-
cular disease and chronic obstructive pulmonary disease. Improvements in assays
for protein markers of inﬂammation have led to many studies on these factors and
their roles in disease. Aims: C-reactive protein (CRP) is one such marker and this
review focuses on the evidence for using CRP as a diagnostic marker and how lev-
els of this protein are modiﬁed according to the smoking status of the patient,
both in terms of the current amount of cigarettes smoked and how CRP levels
change following smoking cessation. Conclusions: Assay of CRP levels may be
useful in monitoring disease progression and determining risk of future cardiovas-
cular complications. However, as this marker is also an indicator of acute inﬂam-
mation and challenges to the immune system, some caution must be exercised in
interpreting the available data on CRP levels in patients with different chronic
comorbidities.
Review Criteria
Literature pertaining to C-reactive protein assay in
chronic diseases in which smoking is a contributory
factor, e.g. coronary heart disease and chronic
obstructive pulmonary disease, was compiled from
the PubMed and ISI databases.
Message for the Clinic
The high-sensitivity test for C-reactive protein is an
assay that is commonly used to determine levels of
infection, but may also be used to measure levels
of underlying inﬂammation. Smoking may increase
circulating levels of CRP, and cessation may cause
a reduction. However, this one assay alone may
not be enough to predict future disease risk as
results could be confounded by other smoking-
related comorbidities.
Linked Comment: Wierzbicki. Int J Clin Pract 2009; 63: 1550–3.
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1634 doi: 10.1111/j.1742-1241.2009.02179.xleads to gross changes in the levels of CRP and
other acute phase proteins. The primary regulators
of CRP and the acute phase proteins are the cyto-
kines interleukin (IL)-6 and IL-1b and tumour
necrosis factor (TNF)-a, which are secreted by neu-
trophil granulocytes and macrophages at sites of
injury. These cytokines bind to cell surface receptors
and initiate an intracellular signalling cascade, which
leads to the activation of several transcription fac-
tors. C⁄EBPb, a member of the CCAAT-enhancer
binding protein transcription factor family, is
directly responsible for inducing the transcription of
CRP (11). Recent elegant experiments demonstrated
the increased binding of C⁄EBPb to the CRP pro-
moter, which is located on the proximal arm of
chromosome 1 (region 1q23.2), following adminis-
tration of IL-6 and IL-1b. This led to an induction
of CRP mRNA within 3 h, increasing to a peak
after 12 h (16).
Once translated, ﬁve 22 kDa monomers of CRP
form a pentameric disc structure, characteristic of a
family of proteins classiﬁed as pentraxins (17). Each
CRP molecule can bind to a variety of ligands, but
shows the highest afﬁnity for phosphocholine resi-
dues. These ligands, either autologous ones such as
those present on damaged cell membranes, apoptotic
cells and in lipoprotein complexes (e.g. low-density
lipoprotein, very low-density lipoprotein) or extrinsic
ones presented by microorganisms, are bound by
CRP, which becomes further aggregated. These
aggregates are then recognised by members of the
classical complement pathway (particularly the C1q
component), thus activating the clearance of the
invading microorganism or damaged cell (12). Fol-
lowing the acute phase response, CRP is cleared from
the plasma, with the protein having a half-life of
approximately 19 h (18).
As well as the major increases in expression of
CRP in response to infection or tissue injury, minor
elevation in CRP levels has been recognised as a pos-
sible marker of disease in systemic conditions (19).
This has been aided by the development of assays to
measure CRP levels with far greater sensitivity than
previous methods (described as high-sensitivity or
hs-CRP assays) and has led to a ﬂood of literature
investigating CRP levels in healthy and diseased indi-
viduals (12,20).
From numerous studies, a large variation in what
is considered to be normal levels of CRP has been
described. For example, the American Heart Associa-
tion deﬁnes a serum CRP concentration of
< 1.0 mg⁄l as being a low risk for developing CVD
and a measurement of > 3.0 mg⁄l as being a high
risk. These values are in contrast to those observed
during acute activation of CRP in response to infec-
tion or inﬂammatory disease, when CRP levels are
>1 0m g⁄l and can become > 500 mg⁄l (21),
although such extreme elevations in CRP levels are
most likely as a result of infection (e.g. 88% of
patients in a study of 130 patients with
CRP > 500 mg⁄l (22)). However, despite the numer-
ous studies that describe the use of serum CRP levels
as a predictive marker for determining risk of CVD,
more recent meta-analyses appear to downplay the
signiﬁcance of CRP as a prognostic marker
(21,23,24).
Do CRP levels vary according to
smoking status?
In recent years, there has been a large volume of
studies, some of which are conﬂicting, in which
serum CRP concentrations have been measured in
parallel to smoking status because of the possible link
between smoking and the induction of inﬂammatory
pathways (25).
Smokers have increased numbers of white blood
cells, mainly because of a particular increase in
polymorphonuclear neutrophils, which are released
from the bone marrow and recruited to inﬂamed
Figure 1 C-reactive protein (CRP) is expressed primarily
in hepatocytes, but can be expressed by other cell types.
Transcription of CRP mRNA is mediated by interleukins-
1b and -6 and transcription factors C⁄EBPb and C⁄EBPd.
Once translated, the mature CRP protein forms a
pentamer, characteristic of the pentraxin family of proteins.
The CRP pentamer has two binding faces: the ligand
binding face binds phospholipids (primarily
phosphocholine) in the presence of calcium ions and may
also bind snRNPs; the effector face of the pentamer binds
substrates including the complement C1q protein and the
Ig receptor FccR. C⁄EBP, CCAAT⁄enhancer Binding
Protein; LDL, low-density lipoprotein; snRNP, small
nuclear ribonucleoprotein; VLDL, very low-density
lipoprotein
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response to lung inﬂammation and are implicated
in the induction of CRP gene expression, may
mediate the stimulation of bone marrow cells (27).
In one study, levels of inﬂammatory markers were
measured in the bloodstream of intermittent smok-
ers 24 h after they had two cigarettes following
9 days of abstinence. TNF-a, IL-10 and IL-1b did
not change, but levels of IL-8 increased after 3 h
(28).
In one of the earlier studies of CRP levels in smok-
ers, and before the advent of assays with higher sensi-
tivities, CRP was found to be signiﬁcantly higher in
male and female smokers compared with non-smokers
(median values of 1.0 mg⁄l and 11.2 mg⁄l for male
non-smokers and smokers, respectively, and for
females 2.0 mg⁄l and 11.6 mg⁄l, respectively) (29).
Such strikingly different values have not been observed
in more recent studies. Furthermore, more than half
(35⁄60) of the smoking cohort from this initial study
had CRP values > 10 mg⁄l, which could be considered
as reﬂecting an inﬂammatory episode (21).
The complexity of cytokine-mediated inﬂamma-
tion is highlighted by a study showing that
although smoking status did correlate with a signiﬁ-
cant elevation in levels of IL-6 and serum amyloid
protein A, another acute phase protein, the increase
in CRP levels observed in smokers was not found
to be statistically signiﬁcant (30). Another larger
study found that mean CRP levels were signiﬁcantly
lower in never-smokers (p < 0.0001) than in current
smokers (31). The CRP assays from these studies
and others mentioned in this text are summarised
in Table 1.
A dose-dependent correlation between CRP and
smoking habits was demonstrated in the ‘Speedwell’
survey of British men. CRP levels were increased
from 1.13 mg⁄l in never-smokers to 1.87, 2.32 and
2.05 mg⁄l in those who smoked 1–14, 15–24 and
> 25 cigarettes, respectively per day (32). However,
another study conducted in people of Japanese eth-
nicity (the Iwate-Kenpoku Cohort study) failed to
identify any signiﬁcant relationship between serum
CRP concentration and the number of cigarettes
smoked per day (33).
Effect of gender on smoking and CRP
status
In one of the few studies that examined gender-
speciﬁc differences for smoking and CRP levels, the
MONICA study from Germany, serum CRP concen-
trations were signiﬁcantly higher in male regular
smokers than male never-smokers (1.92 mg⁄l vs.
1.03 mg⁄l, p < 0.001), but no signiﬁcant difference
was observed in women (1.52 mg⁄l for regular smok-
ers vs. 1.41 mg⁄l for never-smokers) (34).
This gender difference has been observed previously
(35), and the authors of the MONICA study suggest
that the difference in CRP levels may be because of
differing ‘pufﬁng behaviour’ in women. Women tend
to smoke less non-ﬁltered cigarettes, smoke more
low-yield cigarettes and take smaller and shorter puffs.
However, a more recent study takes into account
whether women were taking hormones orally (36). In
this case, a correlation between smoking status and
increased serum CRP concentrations was indeed
observed, but only in those who were not taking oral
hormones, suggesting that such treatments could be
masking changes in CRP levels in the female population.
CRP status in smokers with chronic
diseases
The focus of most of the research attempting to link
CRP expression and incidence of chronic diseases
that are confounded by smoking status has been in
the area of coronary heart disease (CHD), and a
recent review provides a comprehensive analysis of
this ﬁeld (10). Furthermore, the formation of athero-
sclerotic plaques in response to elevated CRP levels
and hence the increased risk of atherothrombosis
because of plaque rupture have been discussed in
great detail by other authors (37,38), and the numer-
ous other pathways and mechanisms by which ciga-
rette smoking can induce inﬂammation and
therefore lead to plaque formation are also reviewed
elsewhere (39). For example, work detailing postmor-
tem analysis of coronary arteries in smokers vs. non-
smokers who died between the ages of 15 and 34 as
a result of external factors (40) showed that
advanced (grade 5) atherosclerotic lesions were far
more prevalent in smokers compared with non-
smokers [Odds ratio (OR) 9.61, 95% conﬁdence
interval (CI) 2.34–39.57]. Although assay of CRP in
these cadavers showed no correlation between smok-
ing status and increased CRP (41), suggesting plaque
formation cannot be simply explained by a single
factor, at least in younger smokers.
About 20% of smokers suffer from COPD, and
one study demonstrated that CRP levels correlated
with pack-years of smoking and predict all-cause
mortality in patients with mild to moderate COPD
in the short-term, although this prediction becomes
weaker with time (42). However, in patients with
moderate to very severe COPD, no relationship
could be identiﬁed between CRP levels and likeli-
hood of survival (43).
Although a relationship between increased CRP
and deaths from respiratory disease has not been
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a yearly decrease in forced expiration volume of sus-
tained smokers. The authors therefore suggested that
combining the results of the CRP assay and forced
expiration volume would help predict outcome, and
thus enable early intervention (42).
In contrast, another study examining CRP levels in
patients with moderate to severe COPD reported
that, although there was a signiﬁcant difference in
CRP levels in the COPD patients, there was no dif-
ference in CRP status between control groups of
smokers and non-smokers (44).
In a study of patients with different forms of
angina, the serum concentration of CRP did not cor-
relate with the type of angina exhibited by the
patient, but did signiﬁcantly correlate with the
patient’s smoking status (p < 0.0001) (45).
Many studies have examined CRP levels in cancer
patients compared with healthy controls and have
identiﬁed a relationship between raised CRP and
disease state (46). However, systematic review of
the data from these studies by these authors sug-
gests that the majority of studies fail to provide
adequate statistical analyses and also fail to take
into account many confounding factors, with the
majority of studies being retrospective (and hence
at risk of introducing bias) (47). A further indepen-
dent study (48) demonstrated an increased likeli-
hood of cancer incidence (OR: 1.3; 95% CI: 1.0,
1.6), when comparing those with a baseline CRP
level of < 1 mg⁄l, with those > 3 mg⁄l, although
this interaction was not signiﬁcant (p = 0.06).
However, both studies showed a signiﬁcant positive
correlation between raised CRP and risk of develop-
ing lung and colorectal cancer. Although smoking
status of the subjects was considered, no analysis of
whether this was a confounding factor in cancer
risk was presented.
Table 1 Summary of CRP assays according to smoking status in different studies
References
Population
studied
No. of
subjects
for each
group
CRP levels (mg⁄l)
in current smokers
(or subgroups)
CRP levels (mg⁄l)
in former smokers
(or subgroups)
CRP levels
(mg⁄l) in
never or non-smokers
Signiﬁcant difference
between current
smokers and
never- or non-smokers
p-value
Helmersson
et al. (30)
642 Swedish men,
age 77 years
Current 55
Former 391
Never 196
1.65 1.8 2.31 Not signiﬁcant
Wannamethee
et al. (31)
2920 British men,
age 60–79 years
Current 391
Former 1503
Never 873
2.53 (95% CI
2.27–2.80)
1.58 (95% CI
1.49–1.66)
1.35 (95% CI
1.26–1.46)
<0 .0001
Lowe
et al. (32)
1690 British men,
age 49–67 years
Current 536
Former 744
Never 272
No. smoked⁄day
1–14 = 1.87
15–24 = 2.32
> 25 = 2.05
Time since quit
> 10 years = 1.36
5–9 years = 1.34
1–4 years = 1.66
< 1 years = 2.10
1.13 < 0.001 (lightest smokers
vs. never-smokers)
0.037 (> 10 year quitters
vs. never-smokers
Oshawa
et al. (33)
1926 Japanese men,
age 40–69 years
Non 661
Former 503
Current 760
0.98 (SD = 1.30) 0.87 (SD = 1.24) 0.79 (SD = 1.20) < 0.01
Fro ¨hlich
et al. (34)
2305 men from
Augsburg, Germany,
age 25–74 years
2211 women from
Augsburg, Germany,
age 25–74 years
Not shown
Not shown
Regular 1.92
Occasional 1.41
Regular 1.52
Occasional 1.15
1.27
1.39
1.03
1.41
Not shown
Not shown
Bermudez
et al. (35)
340 US women, mean
age 60.1 years
Non 43.4%
Former 28.6%
Current 28.0%
0.38 (IQR 0.18–0.83) Not shown 0.30 (IQR 0.13–0.57) 0.032
CI, conﬁdence interval; CRP, C-reactive protein; IQR, interquartile range; SD, standard deviation.
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elevation of CRP is a cause or consequence of
tumour growth, although one study did take this
into account (48), and demonstrated that the mean
time between blood sampling for assay of CRP and
development of cancer was 5.8 years, suggesting the
former. However, if those cases of cancer that were
diagnosed within 2 years of sampling (hence cancers
that may have been present, but not yet diagnosed)
were removed from the analysis, the relationship
between elevated CRP levels and increased risk of
any cancer no longer existed. It is entirely possible
that underlying occult tumours in any subjects dis-
cussed in this review may be inﬂuencing CRP levels.
Without similar long-term longitudinal studies, such
a confounding factor will not become apparent.
Serial assay of CRP levels
Of possible signiﬁcance to the previously discussed
variability is the fact that many of these studies exam-
ining CRP levels in smokers measure the concentration
of this biomarker at a single point in time. Given the
massive induction of CRP in response to acute inﬂam-
mation or infection (up to and exceeding 500 mg⁄l)
and the half-life of the protein in the circulation
(19 h), it is feasible that CRP levels may remain over a
signiﬁcant level for a week after the initial elevation.
When serum concentrations of CRP in male and
female smokers were measured on ﬁve independent
occasions over a 6-week study, they were found to
differ signiﬁcantly over the whole study group (med-
ian 2.7 mg⁄l in smokers vs. 1.2 mg⁄l in non-smokers,
p=0 .05), but these differences were not signiﬁcant
when the individual results from each gender were
examined (49). As this study examined CRP on mul-
tiple occasions, the variability of serum levels in sub-
jects could be calculated, with the within-subject CRP
values varying by more than 100% of the standard
deviation for both smokers and non-smokers, and the
between-subject variability being even higher. The
authors made the salient point that this could be
because of CRP levels being a marker of even the
mildest levels of inﬂammation, such as from a spo-
radic mild acute illness. They did note, however, that
women with consistently higher CRP levels were all
taking oral contraceptives containing oestrogen,
which has been found to correlate signiﬁcantly with
elevated CRP levels (50,51).
CRP and early and indirect exposure
to tobacco smoke
In addition to the reports observing CRP levels in
long-term smokers, studies of adolescent smokers
have also reported signiﬁcantly higher levels of CRP.
When data from a study of adolescents were analy-
sed, an increase in CRP levels was observed, with
heavy smokers having twice the CRP concentration
compared with non-smokers (52). Furthermore, CRP
levels are signiﬁcantly increased in children who are
exposed to secondhand smoke (53).
However, contradicting results have been observed
in never-smoking adults exposed to secondhand
smoke with one group reporting an increase in CRP
levels (54), while a second study did not observe a
signiﬁcant change in CRP status, even though other
biomarkers of CVD risk (ﬁbrinogen, homocysteine)
were increased (55).
CRP levels following smoking
cessation
Most studies that have examined CRP status in for-
mer smokers suggest that levels fail to fall immedi-
ately upon cessation, which reﬂects the fact that the
underlying tissue damage caused by smoking takes
some time to recover (25).
In adults without CHD, CRP levels were signiﬁ-
cantly higher for current smokers compared with
ex-smokers (median 1.9 mg⁄l vs. 1.6 mg⁄l, p < 0.001)
and never-smokers (median 1.1 mg⁄l, p < 0.001). In
addition, CRP levels remained signiﬁcantly higher
than in never-smokers for up to 5 years following
cessation (p < 0.001) (56). Similarly, another study
demonstrated that current smokers had higher levels
of CRP compared with never-smokers (2.53 mg⁄l
vs. 1.35 mg⁄l, p < 0.0001) and former cigarette
smokers (1.58 mg⁄l, p < 0.0001), with the difference
in CRP serum concentration remaining signiﬁcant
between never-smokers and former smokers after
5 years following quitting (31). Furthermore, CRP
levels were reduced to those observed in never-
smokers only in those participants who had quit for
over 20 years.
In the ‘Speedwell’ survey, for those who had quit
smoking for less than a year, CRP levels remained at
2.10 mg⁄l, but subsequently reduced with time to
1.34 mg⁄l 5–9 years and 1.36 mg⁄l > 10 years after
quitting, with this level of CRP still higher than that
of the never-smokers (32).
A study by Fro ¨hlich et al. (34) has one of the lon-
gest follow-up periods, with levels of CRP that were
as low as a mean of 1.25 mg⁄l following 30–55 years
of cessation in male subjects, compared with
1.92 mg⁄l in regular smokers.
As before, most of these surveys only consider CRP
levels at a single point in time, but serial studies fol-
lowing CRP levels before and after smoking cessation
have also been undertaken (57,58). When serum CRP
1638 C-reactive protein and smoking cessation
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smokers and a group who had successfully abstained
from smoking for a year following 8 weeks of trans-
dermal nicotine patch therapy, the levels of CRP were
not signiﬁcantly different from those that were
measured the year before (57). Even though CRP lev-
els did rise slightly in continuing smokers and fell
slightly in those who had quit for a year, the total dif-
ference in change from the mean baseline CRP levels
between the continuing smokers and the quitters was
only 0.66 mg⁄l( p=0 .26). Furthermore, CRP levels
did not signiﬁcantly decrease in a cohort of female
smokers following 6 weeks of smoking cessation with
nicotine replacement therapy (58).
Similarly, no reduction in CRP levels was observed
in smokers who had reduced their cigarette intake by
at least 50% in the 6 months after a baseline CRP
reading was taken (59). Clearly, following the CRP
status of these subjects for a number of years would
conﬁrm how long it may take for CRP levels to nor-
malise following smoking cessation.
Genetic factors that inﬂuence serum
CRP levels
Recent studies have demonstrated that CRP levels are
also inﬂuenced by genetic factors, with heritability
for raised CRP ranging from 39% to 52% in family
and twin studies (60).
CRP is transcribed from chromosome 1, and the
2 kb mRNA that encodes the 22 kDa protein con-
tains two exons, with the single intron having a poly-
morphic GT dinucleotide repeat, which varies in
length from 9 to 25 copies (61). The number of
these microsatellite repeats varies between races, with
the three most common genotypes GT
16⁄ 16,G T
16 ⁄ 21
and GT
21⁄ 21 found in 78% of Caucasians, but in
only 20% of African-Americans (61). These geno-
types are associated with low CRP levels but, in con-
trast, individuals with a GT
18 ⁄ 18 or GT
20 ⁄ 20 genotype
have signiﬁcantly higher serum CRP, although the
mechanisms underlying this change in expression
have yet to be elucidated. In addition, there have
been at least 40 single nucleotide polymorphisms
(SNPs) identiﬁed in the CRP gene locus (60),
although only eight of the SNPs have been identiﬁed
to occur with > 5% frequency (62) with the majority
of SNPs found in the 3¢ untranslated region or the
promoter. This latter observation suggests that
upstream mediators of CRP expression may be
responsible for differing effects on the genetic vari-
ants. For those SNPs found in the 3¢ untranslated
region, they could be exerting differential effects on
the stability of the message, or even altering binding
sites for microRNAs (miRNA), which could in turn
affect the translational regulation of the mRNA. To
date, no reports of miRNA regulation of CRP expres-
sion have been published, but miR-120 has been
shown to be involved in the translational repression
of pentraxin A1 (63).
It is perhaps disappointing that, despite the huge
amount of data being generated on the disease risks
associated with certain polymorphisms and CRP lev-
els, no direct link has yet been established as to
whether any of the known polymorphisms in the
CRP gene and their effect on CRP status is con-
founded by the smoking status of the subject.
Conclusions
Since the development of high-sensitivity CRP assays,
this acute phase protein has been examined in a large
number of studies, and increased CRP has been
found to be associated with increasing age, body
mass index, weight and reduced ﬁtness levels. Signiﬁ-
cant differences in CRP levels relative to socioeco-
nomic position, ethnicity and gender have also been
reported (12,20).
These results are in addition to the numerous
studies that examine CRP in patients with CVD and
many other diseases in which smoking is a known
aggravating factor. However, as CRP levels can
change so rapidly in response to even the most
minor of challenges to the immune system and also
to tissue injury, several authors have cautioned
against the view that CRP can be used as a prognos-
tic marker in assessing future disease risk (21,23,24).
The ambitious Emerging Risk Factors Collabora-
tion is currently in the process of collecting data on
circulating lipid factors and markers of inﬂamma-
tion, including CRP, from over 1.1 million partici-
pants (64). This meta-analysis may ﬁnally be able to
determine whether there is a deﬁnitive relationship
between smoking status and CRP levels and may also
be able to distinguish whether CRP is itself a causal
risk factor in CVD or a marker reﬂecting the status
of other cardiovascular risk factors (10). Measure-
ment of CRP levels before and following smoking
cessation may be a useful indicator of any decrease
in risk of CVD or COPD for the patient, and there-
fore encourage long-term abstinence. If such assays
were undertaken, however, it would be important to
consider on a case-by-case basis whether any acute
confounding events precipitated the attempt at
smoking cessation [e.g. myocardial infarction (MI)].
In these cases, the precipitating event would itself
cause an initial elevation in CRP levels and hence be
inappropriate as a measure of encouragement.
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